Modern pharmacotherapy of Hodgkin's disease;Moderne pharmakotherapie des morbus Hodgkin

Internist

Volumn 45, Issue 1, 2004, Pages 93-101

  Josting, A ^a   Behringer, K ^a   Engert, A ^a   Diehl, V ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chemotherapy; Hodgkin's disease; Lymphomas; Radiation therapie; Staging

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; HODGKIN DISEASE; HUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; RISK FACTOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0842278739     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-003-1094-2     Document Type: Review

References (42)

1. Jones E, Mauch P (1996) Limited radiation therapy for selected patients with stages IA and IIA Hodgkin's disease. Semin Radiation Oncol 6:162-171
2. Biti G, Cimino G, Cartoni C et al. (1992) Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hogkin's disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 10: 378-382
3. Kaplan HD (1980) Hodgkin's disease. Harward University Press, Cambridge
4. Hancock SL, Tucker MA, Hoppe RT (1993) Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270:1949
5. Ng AK, Bernardo P, Weller E et al. (2002) Long-term survival and competing causes of death in patients with early-stage-Hodkgin's disease treated at age 50 or younger. J Clin Oncol 20: 2101-2108
6. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, van't Veer MB, Bartelink H, van Leeuwen FE (2003) Long-term cause-specific mortality of patients treated for Hodgkin's Disease. J Clin Oncol 21: 3431-3439
7. Duhmke E, Franklin J, Pfreundschuh M et al. (2001) Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19: 2905-2914
8. Sieber M, Franklin J, Tesch H et al. (2002) Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's Disease: results of the German Hodgkin's Lymphoma Study Group (GHSG) Trial HD7. Blood 100: A341
9. Horning SJ, Hoppe RT, Hancock SL, Rosenberg SA (1988) Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 6: 1822-1831
10. Radford JA, Cowan RA, Ryder WDJ (1996) Four weeks of neo-adjuvant chemotherapy significantly reduces the progression rate in patients treated with limited field radiotherapy for clinical stage (CS) IA/IIA Hodgkin's disease. Results of a randomised pilot study. Ann Oncol 7: Abstr 66
11. Hagenbeek A, Carde P, Noordijk E et al. (1997) Prognostic factor tailored treatment of early stage Hodgkin's disease. Results from a prospective randomized phase III clinical trial in 762 patients (H7 study). Blood 90 (Suppl): Abstr 2603
12. Bates NP, Williams MV, Bessel EM, Vaughan Hudson G, Vaughan Hudson B (1994) Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: A British National Lymphoma Investigation pilot study. J Clin Oncol 12: 288-296
13. Canellos GP, Anderson JR et al. (1992) Chemotherapy of advanced Hodgkin: s disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med 327:1478-1484
14. Duggan D, Petroni G, Johnson J et al. (1997) MOPP/ABV versus ABVD for advanced Hodgkin's disease - preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC). Proc Am Soc Clin Oncol 16: Abstr 43
15. Zittoun R, Audebert A, Hoerni B et al. (1985) Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol 3: 207-214
16. Santoro A, Bonfante V, Viviani S et al. (1996) Subtotal nodal (STNI) vs. involved field (IFRT) irradiation after 4 cycles of ABVD in early stage Hodgkin's disease. Proc Am Soc Clin Oncol 15: Abstr 1271
17. Engert A, Schiller P, Josting A et al. (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21: 3601-3608
18. Longo DL, Young RC, Wesley M, Hubbard M, Duffey PL, Jaffe ES, DeVita VT (1986) Twenty years of MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 4: 1295-1306
19. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (1975) Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboximide versus MOPP. Cancer 36: 252-259
20. Santoro J, Bonadonna G, Valagussa P et al. (1987) Longterm results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5: 27
21. Canellos GP, Anderson JR, Propert KJ et al. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327: 1478-1484
22. Goldie JH, Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep 63: 1727-1733
23. Duggan DB, Petroni GR, Johnson JL et al. (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21: 607-614
24. Connors JM, Klimo P, Adams G et al. (1997) Treatment of advanced Hodgkin's disease with chemotherapy - comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15: 1638-1645
25. Sieber M, Rüffer U, Tesch H et al. (1997) Rapidly alternating COPP+ABV+IMEP (CAI) is equally effective as alternating COPP+ABVD (CA) for Hodgkin's disease: final results of two randomized trials for intermediate (HD5 protocol) and advanced (HD6 protocol) stages. Blood 90 (Suppl): Abstr 2605
26. Diehl V, Sieber M, Rüffer U et al. (1997) BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 8: 143-148
27. Diehl V, Franklin J, Pfreundschuh M et al. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348: 2386-2395
28. Löffler M, Brosteanu O, Hasendever D et al. (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 16: 818-829
29. Horwich A, Specht L, Ashley S (1997) Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 33: 848-856
30. Roach MD, Brophy N, Cox R (1990) Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol 8: 623-629
31. Fisher R, De VV, Hubbard S (1979) Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 90: 761-766
32. Josting A, Franklin J, May M et al. (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin lymphoma registered in the database of the German Hodgkin Lymphoma Study Group (GHSG).J Clin Oncol 20:221-230
33. Bierman P, Bagin R, Jagannath (1993) High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol 4: 767-771
34. Reece D, Barnett M, Shepherd J (1995) High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 86: 451-458
35. Josting A, Katay I, Rueffer U (1998) Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 9: 289-295
36. Linch D, Winfield D, Goldstone A (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 341: 1051-1054
37. Schmitz N, Pfistner B, Sextro M et al. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stemcell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359: 2065-2071
38. Norton L, Simon R (1986) The Norton-Simon hypothesis revisited. Cancer Treat Rep 70: 163-169
39. Josting A, Rudolph C, Reiser M et al. (2002) Time intensified DHAP - An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 13: 1628-1635
40. Josting A, Rudolph C, Mapara M et al. (2003) Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma - Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). (submitted)
41. Engert A, Pohl C, Diehl V (1992) Experimental therapy in Hodgkin's disease. Ann Oncol 3(Suppl): 97
42. Borchmann P, Schnell R, Fuss I et al. (2002) Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 100: 3101-3107